Acorn Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Acorn Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-28	Closed	-$4K	–	785
2018 Q1	$4K	Hold	28	–	–	﹤0.01%	664
2017 Q4	$4K	Buy	+28	New	+$4.15K	﹤0.01%	636

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Acorn Wealth Advisors's VRTX Position: Q2 2018 in Review

Acorn Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 28 shares — an estimated $4K sold.

Acorn Wealth Advisors first reported a position in VRTX in Q4 2017 and held it in 2 quarters. The position peaked at $4K in Q1 2018. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Acorn Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Acorn Wealth Advisors sold 28 Vertex Pharmaceuticals shares in Q2 2018, an estimated $4K.
Acorn Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 2 quarters.
Acorn Wealth Advisors's Vertex Pharmaceuticals position peaked at $4K in Q1 2018.
689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Acorn Wealth Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.